389 related articles for article (PubMed ID: 35072947)
21. A Tale of 2 Morphologies: Diagnostic Pitfalls in
Sharma AE; Parilla M; Wanjari P; Segal JP; Antic T
Int J Surg Pathol; 2021 Feb; 29(1):21-29. PubMed ID: 32886007
[TBL] [Abstract][Full Text] [Related]
22. NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.
Pei J; Cooper H; Flieder DB; Talarchek JN; Al-Saleem T; Uzzo RG; Dulaimi E; Patchefsky AS; Testa JR; Wei S
Mod Pathol; 2019 May; 32(5):710-716. PubMed ID: 30622287
[TBL] [Abstract][Full Text] [Related]
23. "Oncocytoid Renal Cell Carcinomas After Neuroblastoma" Represent TSC -mutated Eosinophilic Solid and Cystic Renal Cell Carcinomas : Association With Prior Childhood Malignancy and Multifocality With Therapeutic Implications.
Argani P; Medeiros LJ; Matoso A; Baraban E; Lotan T; Pawel BR; McKenney JK; Mehra R; Falzarano SM; Pallavajjalla A; Lin MT; Patel S; Rawwas J; Bendel AE; Gagan J; Palsgrove DN
Am J Surg Pathol; 2023 Dec; 47(12):1335-1348. PubMed ID: 37522346
[TBL] [Abstract][Full Text] [Related]
24. Melanotic MiT family translocation neoplasms: Expanding the clinical and molecular spectrum of this unique entity of tumors.
Saleeb RM; Srigley JR; Sweet J; Doucet C; Royal V; Chen YB; Brimo F; Evans A
Pathol Res Pract; 2017 Nov; 213(11):1412-1418. PubMed ID: 28969862
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization.
Beaumont M; Dugay F; Kammerer-Jacquet SF; Jaillard S; Cabillic F; Mathieu R; Verhoest G; Bensalah K; Rioux-Leclercq N; Belaud-Rotureau MA;
Hum Pathol; 2019 Oct; 92():81-90. PubMed ID: 31437522
[TBL] [Abstract][Full Text] [Related]
26. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.
Wang XM; Zhang Y; Mannan R; Skala SL; Rangaswamy R; Chinnaiyan A; Su F; Cao X; Zelenka-Wang S; McMurry L; Xiao H; Spratt DE; Sangoi AR; Shao L; Betz BL; Brown N; Tickoo SK; McKenney JK; Argani P; Gupta S; Reuter VE; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Mod Pathol; 2021 Aug; 34(8):1596-1607. PubMed ID: 33854184
[TBL] [Abstract][Full Text] [Related]
27. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
[TBL] [Abstract][Full Text] [Related]
28. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.
Argani P; Hicks J; De Marzo AM; Albadine R; Illei PB; Ladanyi M; Reuter VE; Netto GJ
Am J Surg Pathol; 2010 Sep; 34(9):1295-303. PubMed ID: 20679884
[TBL] [Abstract][Full Text] [Related]
29. Integrative clinical and molecular characterization of translocation renal cell carcinoma.
Bakouny Z; Sadagopan A; Ravi P; Metaferia NY; Li J; AbuHammad S; Tang S; Denize T; Garner ER; Gao X; Braun DA; Hirsch L; Steinharter JA; Bouchard G; Walton E; West D; Labaki C; Dudani S; Gan CL; Sethunath V; Carvalho FLF; Imamovic A; Ricker C; Vokes NI; Nyman J; Berchuck JE; Park J; Hirsch MS; Haq R; Mary Lee GS; McGregor BA; Chang SL; Feldman AS; Wu CJ; McDermott DF; Heng DYC; Signoretti S; Van Allen EM; Choueiri TK; Viswanathan SR
Cell Rep; 2022 Jan; 38(1):110190. PubMed ID: 34986355
[TBL] [Abstract][Full Text] [Related]
30. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
31. Re-evaluation of histological type by immunohistochemical and genetic study of transcription factors (TFE3 and TFEB) of VHL gene mutation-negative clear cell renal cell carcinoma and other special types of renal tumor.
Kuroda N; Kawada C; Tamura K; Hiroi M; Hes O; Michal M; Wada Y; Inoue K; Ohara M; Mizuno K; Shuin T; Lee GH
Med Mol Morphol; 2011 Mar; 44(1):46-51. PubMed ID: 21424937
[TBL] [Abstract][Full Text] [Related]
32. Expanding the histomorphologic spectrum of TFE3-rearranged perivascular epithelioid cell tumors.
Maloney N; Giannikou K; Lefferts J; Bridge JA; Linos K
Hum Pathol; 2018 Dec; 82():125-130. PubMed ID: 29626599
[TBL] [Abstract][Full Text] [Related]
33. MiT family translocation renal cell carcinoma.
Argani P
Semin Diagn Pathol; 2015 Mar; 32(2):103-13. PubMed ID: 25758327
[TBL] [Abstract][Full Text] [Related]
34. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
35. Histological and molecular characterization of TFEB-rearranged renal cell carcinomas.
Wyvekens N; Rechsteiner M; Fritz C; Wagner U; Tchinda J; Wenzel C; Kuithan F; Horn LC; Moch H
Virchows Arch; 2019 May; 474(5):625-631. PubMed ID: 30706129
[TBL] [Abstract][Full Text] [Related]
36. NONO::TFE3 fusion cutaneous epithelioid and spindle cell tumor: A case series.
See SHC; Olivares S; Kulkarni M; Dhillon SK; Fumero-Velazquez MS; Hagstrom MNE; Gerami P
J Cutan Pathol; 2023 Nov; 50(11):956-962. PubMed ID: 37606377
[TBL] [Abstract][Full Text] [Related]
37. TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
Yin X; Wang B; Gan W; Zhuang W; Xiang Z; Han X; Li D
J Exp Clin Cancer Res; 2019 Mar; 38(1):119. PubMed ID: 30849994
[TBL] [Abstract][Full Text] [Related]
38. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R
BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159
[TBL] [Abstract][Full Text] [Related]
39. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
[TBL] [Abstract][Full Text] [Related]
40. Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.
Zhang HZ; Xia QY; Wang SY; Shi MJ; Wang SY
Virchows Arch; 2022 May; 480(5):999-1008. PubMed ID: 35099634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
